Business
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing IBI324 (Ollin R&D code:OLN324), a next-generation VEGF/Ang2 bi
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing IBI324 (Ollin R&D code:OLN324), a next-generation VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in over 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). OLN324's up to 60-fold higher anti-Ang2 potency together with a smaller protein format and a higher molar dose gives OLN324 a differentiated, first-line standard of care profile.","length":928,"tagName":"p"},{"type":"text","content":"OLN324 demonstrated both faster and greater retinal drying versus faricimab in patients with DME, with OLN324 4mg treated patients experiencing mean improvements in retinal drying that were ~75% greater than faricimab at Week 1 (-79 µm vs. -45 µm mean change in central subfield thickness or CST, respectively), and ~50% greater at Week 12 (-180 µm vs. -121 µm), measured using optical coherence tomography (OCT). Additionally, nearly 90% of OLN324 4mg treated patients achieved absence of DME at Week 12, defined as CST < 325 µm, as compared to 57% of faricimab patients.","length":575,"tagName":"p"},{"type":"text","content":"All treatment groups yielded equivalent anatomic outcomes in patients with wAMD, with rapid improvements in OCT mean CST as early as Week 1 that were sustained through Week 12. Patients across all treatment groups experienced rapid and sustained mean gains in vision (best-corrected visual acuity, or BCVA) with numerically greater improvements at Week 12 with OLN324 than faricimab in both DME and wAMD.","length":409,"tagName":"p"},{"type":"text","content":""DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases. The difference in speed and extent of retinal drying observed with OLN324 versus faricimab, the hi...